Ivabradina Krka

Ivabradine, the active ingredient in Ivabradina Krka, is a selective If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate to treat chronic stable angina and heart failure in adult patients.

GNH USA supplies Ivabradina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Krka acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic. - Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by decreasing heart rate.

Ivabradina Krka may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate falls below the expected range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Persistent visual impairment or retinal disturbances.

Before prescribing Ivabradina Krka, clinicians should consider several safety measures. - Cardiac monitoring: assess baseline heart rate and rhythm. - Concomitant bradycardic agents: avoid excessive heart‑rate reduction when combined with beta‑blockers or digoxin. - Severe hepatic impairment: use with caution, dose adjustment may be required. - Pregnancy: safety not established; avoid unless clearly needed. - Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradina Krka can interact with other medicines that affect its metabolism or heart‑rate control.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce efficacy. - Other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate slowing.

Moderate Interactions (Monitor Closely): - Calcium‑channel blockers (verapamil, diltiazem): may raise plasma levels. - Moderate CYP3A4 inhibitors (e.g., fluoxetine, erythromycin): require careful monitoring. - Antacids or high‑fat meals: can affect absorption; observe therapeutic response.